MHLW OKs RCC Indication for Opdivo, Approval Changes to Other Drugs

August 29, 2016
The Ministry of Health, Labor and Welfare (MHLW) on August 26 approved Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) for an additional indication of renal cell carcinoma (RCC). Here is the list of drugs approved on the same day for new...read more